Novel biodegradable stents in the treatment of bronchial stenosis after lung transplantation

Eur J Cardiothorac Surg. 2011 Sep;40(3):619-24. doi: 10.1016/j.ejcts.2010.12.047. Epub 2011 Feb 21.

Abstract

Objective: To evaluate the safety and effectiveness of novel biodegradable (BD) stents to treat bronchial anastomotic stenosis in patients after lung transplantation.

Methods: Twenty BD stents were implanted endoscopically in six patients (median age 41.5 years (range 35-57 years)) with post-transplant bronchial anastomotic stenoses, between 2006 and 2010. All stents were custom-made from bio-absorbable polydioxanone (PDS). The median stent diameter was 12 mm (8-17 mm) and median length was 20mm (12-30 mm). All patients were evaluated clinically, by bronchoscopy and high-definition computed tomography (CT).

Results: The stenosis was initially relieved in all cases. There was no bleeding, perforation or displacement after BD stent implantation. Four patients needed multiple stenting for anastomotic re-stenosis. Median time to any re-stenting was 5 months (2-15 months). There was one sudden death, 1 year after the last BD stent implantation, from a pulmonary embolus. All five survivors are in good clinical condition up to 4 years' follow-up (median 40 months, range 7-48 months) since first stenting and intervention-free up to 44 months (median 24 months, range 7-44 months).

Conclusions: This small pilot study shows that BD stents are a safe, effective and reliable alternative to classical metallic stents in patients with anastomotic stenosis after lung transplantation, and may avoid the need for permanent stenting.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants*
  • Adult
  • Airway Obstruction / etiology
  • Airway Obstruction / surgery
  • Anastomosis, Surgical / adverse effects
  • Bronchial Diseases / etiology
  • Bronchial Diseases / surgery*
  • Bronchoscopy
  • Constriction, Pathologic / etiology
  • Constriction, Pathologic / surgery
  • Epidemiologic Methods
  • Humans
  • Lung Transplantation / adverse effects*
  • Middle Aged
  • Polydioxanone
  • Prosthesis Design
  • Stents*
  • Treatment Outcome

Substances

  • Polydioxanone